inbs stock — Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions, Inc. (INBS)
inbs stock refers to Intelligent Bio Solutions, Inc., a U.S.-based medical-technology company listed on the NASDAQ under the ticker INBS. This article summarizes the company’s business focus on non-invasive diagnostic and drug-screening technologies, headquarters and founding background, market classification as a micro-/sub-micro-cap, and provides a structured reference for investors and researchers.
Company Overview
Intelligent Bio Solutions, Inc. (INBS) develops non-invasive diagnostic and biosensor technologies focused on fingerprint sweat analysis for drug screening and biosensor platforms for health monitoring. Founded in 2016 and headquartered in New York, the company targets employers, transportation operators, clinical laboratories, and other markets that require rapid, on-site screening. The company positions itself to sell both capital units and recurring consumables such as single-use cartridges.
History and Corporate Timeline
Key milestones for the company include its founding in 2016, subsequent development of fingerprint and biosensor technologies, and a public listing. The company completed an initial public offering and listing on NASDAQ in December 2020. Since listing, inbs stock has experienced a series of financings and public offerings reported in SEC filings and press releases, including registered direct offerings and at‑the‑market sales that are typical for small-cap life-sciences companies seeking growth capital. The company has also filed corporate actions such as reverse split proposals at times to meet listing requirements or to address share-structure considerations.
As of December 2020, according to SEC filings and the company’s press releases, the IPO took place in December 2020. Subsequent public filings and reporting documents through 2023 and 2024 documented follow-on registered offerings and equity financings; readers should consult the company’s most recent SEC filings for precise dates and amounts.
Business Segments and Products
Intelligent Fingerprinting Products (IFPG)
The company’s flagship commercial approach centers on fingerprint sweat drug screening. Intelligent Fingerprinting Products (IFPG) are designed to detect recent drug use via trace amounts of drugs in sweat captured from a fingerprint. The product efforts are aimed at workplace testing, transportation and safety-sensitive industries, and clinical or occupational-health settings where non-invasive, rapid screening can reduce the need for blood or urine collection.
Claims around IFPG include rapid time-to-result and non-invasive sample collection that can improve compliance and user acceptability. The business model emphasizes sales of screening devices and recurring revenue from proprietary cartridges or test kits used per test.
Saliva Glucose Biosensor Platform and Other Biosensors
Beyond fingerprint drug-screening, Intelligent Bio Solutions has described research and development work on biosensor platforms intended for glucose monitoring and other diagnostic applications. These biosensor initiatives are typically in pre-commercial or development stages; the company has cited ongoing R&D, prototype development, and laboratory validation activities in filings and press releases.
Consumables and Cartridges
An important commercial focus for inbs stock is recurring consumables revenue. The company’s revenue model depends significantly on single-use cartridges and tests that accompany detection units. Press releases and investor communications have highlighted cartridge shipment volumes and “record cartridge sales” in periodic updates; readers should consult the cited press materials for the specific quantities and dates.
Technology and Intellectual Property
Intelligent Bio Solutions’ core technologies combine microfluidics, electrochemical biosensing, and analytical chemistry to detect analytes from fingerprint sweat and other non-invasive matrices. The reported IP strategy includes patent filings and trade-secret protection around sample collection methods, cartridge design, sensor chemistries, and data-analysis algorithms.
Company disclosures and press materials often emphasize validation studies and claimed performance characteristics such as sensitivity to recent use windows for specific substances. As with any early-stage diagnostic technology, independent validation and peer-reviewed publications are important complements to company-reported performance metrics.
Regulatory Path and Approvals
Like many diagnostic-device companies, Intelligent Bio Solutions describes activities toward regulatory clearances and pathways. Company statements have referenced work on U.S. FDA 510(k) submissions for certain device classes and interactions with regulators, although at times the devices remain subject to additional clinical validation or regulatory review. Regulatory timelines for medical devices can be lengthy and depend on the device classification, study results, and regulator feedback.
As of press reporting and company updates through 2023–2024, progress toward formal regulatory clearances was ongoing; specifics are available in the company’s SEC filings and regulatory announcements. Investors and partners are advised to consult the most recent 510(k) status or public filings for up-to-date regulatory milestones.
Market Listing and Trading Information
Ticker and Exchange: Intelligent Bio Solutions trades on NASDAQ under the ticker INBS. The stock is commonly referred to as inbs stock in market commentary and on financial platforms.
IPO and Share Structure: The company completed its public listing in December 2020. Since listing, share counts, float, and outstanding shares have changed due to follow-on offerings, equity issuances, and potential corporate actions. inbs stock is classified as a micro-cap or sub-micro-cap name, which often implies lower market capitalization and limited liquidity when compared with larger listed companies.
Trading Characteristics: inbs stock has historically shown volatile daily price swings and periods of low average trading volume, reflecting typical small-cap dynamics. Market pages and community sentiment often highlight high volatility around corporate announcements, financing events, and product or regulatory news.
Financial Summary
Revenue and Profitability: As a med-tech development-stage company with commercial efforts concentrated on device rollouts and consumables, Intelligent Bio Solutions has reported revenues tied to device sales and cartridge shipments. Simultaneously, the company has reported net losses, reflecting ongoing R&D, commercialization costs, and corporate overhead typical of early-stage medical-technology companies.
Market Capitalization and Liquidity: inbs stock is categorized as a micro-cap; market-cap figures and daily volume can change materially in short timeframes. For precise, up-to-date numerical figures (market capitalization, average daily volume, and the most recent revenue/earnings data), consult live market pages, the NASDAQ listing information, or the company’s recent SEC filings.
Financing Events: The company has raised capital through registered offerings, at-the-market programs, and possible private placements as documented in 8-K filings and press releases. These financing avenues are common for small public companies to fund operations and scale commercial programs.
Stock Price History and Corporate Actions
Historical Price Behavior: inbs stock has experienced wide historical swings driven by news flow, product milestones, funding announcements, and general small-cap market dynamics. Investors following the name will often see sharp intraday moves on news releases and social-media-driven interest.
Corporate Actions: The company has, at times, filed or discussed reverse stock split proposals, offerings, and other corporate actions in SEC filings. Such actions are frequently taken by small-cap issuers for liquidity management or to maintain exchange listing standards; check the company’s 8-Ks for specific resolutions and shareholder votes.
Ownership and Shareholder Structure
Insider Holdings: Company founders, executives, and board members typically hold a portion of outstanding shares; insider holdings and transactions are disclosed in SEC filings and Form 4 reports. Insider ownership levels can shift after financing rounds or equity awards.
Institutional and Retail Holders: Due to its micro-cap classification, inbs stock often has limited institutional ownership compared with larger public companies. Retail investors and small institutional holders can form a meaningful portion of the float. Publicly available institution-holding snapshots on market data pages provide periodic lists of holders, but these should be cross-checked against the company’s latest filings for accuracy.
Partnerships, Contracts, and Commercial Activity
Commercial Wins and Tenders: The company has publicized contract wins and participation in tenders for transportation and workplace testing. Examples in company press releases include pilot programs and tender participation in markets such as the UK and initiatives in Latin America and the Middle East. These releases often state anticipated order sizes or deployment plans; however, actual revenue depends on successful rollouts and fulfillment.
Distribution and Integration: Intelligent Bio Solutions has described partnerships for distribution, localization, and system integration to support deployments outside its domestic market. Such partnerships are core to the go-to-market strategy for small diagnostics companies that depend on local distributors for regulatory, logistic, and commercial support.
Recent Developments and News
As of the latest public communications recorded in corporate press releases and financial news pages, common themes in updates from the company include cartridge shipment milestones, conference participation, prototype validation progress, and funding events. For example, the company has reported “record cartridge sales” in certain quarterly communications and has announced registered offerings to raise working capital; each press release includes a date and contextual numbers.
Readers should consult the company’s press releases and SEC 8-K filings for dated announcements. As of press reports in 2023 and 2024, the company continued to highlight commercial traction in test cartridge shipments combined with capital raises to support expansion. Specific dates and exact figures for cartridge volumes and financing amounts should be verified in the cited documents.
Corporate Governance and Management
Key Executives and Board: Intelligent Bio Solutions’ senior management typically includes a Chief Executive Officer, Chief Financial Officer, and other functional heads overseeing R&D and commercialization. Names and biographies of the CEO and board members are disclosed in the company’s periodic reports and proxy statements.
Governance Disclosures: Executive compensation, board composition, and related-party arrangements are detailed in DEF 14A proxy statements and annual reports. Small public companies often include stock-based compensation as part of executive pay, and shareholders should review proxy materials for governance details.
Risks and Controversies
Micro-cap and Early-Stage Risks: inbs stock shares many risks common to development-stage med-tech companies, including limited liquidity, high historical volatility, negative operating cash flow, and the potential for dilution from future financings. Equity offerings and at-the-market programs can dilute existing shareholders if additional shares are issued.
Regulatory and Commercialization Risks: The company’s commercial success depends heavily on regulatory approvals (where required), third-party validation, successful commercial rollouts, and acceptance by customers in target industries such as transportation and workplace testing. Failure to meet regulatory or performance milestones could materially impact business prospects.
Operational and Execution Risks: Manufacturing scale-up, supply-chain delays, and quality-control issues can affect the ability to deliver devices and consumables at scale. Small companies may also face challenges retaining key personnel or securing long-term distribution agreements.
SEC Filings and Reporting
Primary Filings to Consult: Investors and researchers should consult the company’s Form 10-K (annual report), Form 10-Q (quarterly reports), Form 8-K (material event notices), and DEF 14A (proxy statement) for authoritative disclosures on financials, governance, and material events. Form 4 filings disclose insider transactions and changes in beneficial ownership.
Where to Verify: SEC filings are the primary, authoritative records for financial statements, related-party transactions, share counts, and event-driven disclosures. Cross-reference press releases with SEC filings for confirmation of material facts such as financing amounts and contractual terms.
Analyst Coverage and Market Sentiment
Analyst and Retail Coverage: inbs stock receives limited sell-side analyst coverage relative to larger-cap healthcare names. Commentary often comes from retail platforms, micro-cap research sites, and market-data aggregators. Retail sentiment can be found on social platforms where small-cap names are discussed actively, sometimes leading to high intraday volatility.
Interpretation: Due to relatively sparse institutional coverage, market sentiment for inbs stock can be dispersed, and retail-driven interest may cause price swings that are not strongly anchored to fundamental valuation metrics.
See Also
- Non-invasive diagnostics
- Biosensor technology
- FDA 510(k) clearance process
- Micro-cap investing considerations
References and External Sources
This article is based on company disclosures, market-data pages, and press reporting. Primary sources to consult for verification include the company’s SEC filings (10‑K, 10‑Q, 8‑K, DEF 14A), Nasdaq company pages, official press releases reported via GlobeNewswire, and market-data pages such as TradingView, Finviz, MarketChameleon, Macrotrends, StockTwits, Seeking Alpha and major financial news portals. Where specific dates are mentioned, readers should cross-check the quoted press release or filing for the precise statement and figures.
Example dated reporting notes:
- As of December 2020, according to SEC filings and company announcements, the company completed its IPO and listing on NASDAQ.
- As of company press releases in 2023–2024, the company reported cartridge shipment milestones and completed registered offerings to raise capital for commercial expansion (see the company’s 8-K and press release dates in those years).
How to Follow inbs stock and Company Updates
For the latest market price and trading volume for inbs stock, consult live quote pages on regulated market-data platforms and the NASDAQ listing page. For authoritative details on financings, ownership changes, and regulatory milestones, review the company’s SEC filings and dated press releases. (Note: this article does not provide investment advice.)
If you plan to monitor or trade equities including small-cap med-tech names, consider using reputable trading platforms and checking company filings before making decisions. When using web3 wallets or custody solutions for related activities, the Bitget Wallet is suggested as a primary option for secure wallet management; for trading services, consider Bitget as a recommended platform for executing trades and monitoring markets. Always verify ticker symbols and cross-check against official exchange listings.
Final Notes and Next Steps
This article aimed to present a neutral, structured reference on inbs stock (Intelligent Bio Solutions, Inc.) including business description, product lines, regulatory posture, market-listing facts, financial and corporate governance items, and the principal risks typical for micro-cap diagnostics companies. For specific numeric metrics such as current market capitalization, latest quarterly revenue, and up-to-the-minute trading volume, consult real-time market-data providers and the company’s most recent SEC filings.
Further exploration: review the latest 10‑Q/10‑K for audited financials, subscribe to the company’s press releases for dated announcements, and check NASDAQ and market-data pages for live price and volume. To manage trades or track the stock, consider using Bitget for trading services and Bitget Wallet for custody where applicable.
Want to keep monitoring inbs stock? Start by checking the company’s latest SEC filings and press releases, then follow market-data pages for live quotes and trading volume updates.
